H. Tukiainen et al., Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma, RESP MED, 94(7), 2000, pp. 678-683
The importance of early initiation of inhaled steroids even in mild asthma
has been documented in several studies. It is not, however, clear whether t
he treatment should be started with a high or a low dose of the inhaled ste
roid. We have compared the effects of high and low dose inhaled steroid, bu
desonide, in patients with newly detected asthma.
We studied 101 adult patients with newly detected bronchial asthma who were
without inhaled steroid or any regular pharmacological treatment for their
asthma. The patients were randomly allocated to two treatment groups: one
to receive 800 mu g inhaled budesonide per day and the other to receive 200
mu g inhaled budesonide per day. The drugs were given with a Turbuhaler(R)
dry powder inhaler. During the 3-month treatment period, no significant di
fferences between the treatment groups were noted in morning or evening PEF
values, in spirometric parameters, in asthmatic symptoms or in the use of
rescue beta(2)-agonists. The decrease in bronchial hyperresponsiveness was,
however, more marked in the high dose budesonide group, reaching a borderl
ine significance (P = 0.10 high vs. low dose budesonide). In addition, in s
erum markers of asthmatic inflammation significant differences were shown b
etween the treatment groups. The decrease in the number of blood eosinophil
s during the treatment was more marked in the high dose budesonide group (P
= 0.02; high vs. low dose budesonide). In serum ECP no change was observed
in the low hose budesonide group, but a marked decrease in the high-dose b
udesonide group (P = 0.008; high vs. low dose budesonide). The change was e
ven more marked with regard to serum EPX (P = 0.005; high vs, low dose bude
sonide).
Our results support the view that the treatment of newly detected asthma sh
ould be started with a high dose of inhaled steroid. The low dose may not b
e enough to suppress asthmatic inflammation despite good clinical primary r
esponse.